. "Z(MSM0021620816)" . . "Praha" . . "Gal\u00E9n" . . . . "Antipsychotiky indukovan\u00E9 myokarditidy a kardiomyopatie" . . "RIV/00216208:11150/06:00004051!RIV07-MSM-11150___" . "RIV/00216208:11150/06:00004051" . "80-7262-420-2" . "Nemocn\u00E1 du\u0161e - nemocn\u00FD mozek : klinick\u00E1 zku\u0161enost a fakta" . . "Mal\u00FD, Radovan" . "Masopust, Ji\u0159\u00ED" . "T\u016Fma, Ivan" . "[1783262C4488]" . "Antipsychotiky indukovan\u00E9 myokarditidy a kardiomyopatie" . . . . "Antipsychotiky indukovan\u00E9 myokarditidy a kardiomyopatie"@cs . . "Antipsychotiky indukovan\u00E9 myokarditidy a kardiomyopatie"@cs . "Myocarditis and cardiomyopathy induced by antipsychotics"@en . "3"^^ . "myocarditis; cardiomyopathy; antipsychotics"@en . "Myocarditis and cardiomyopathy induced by antipsychotics"@en . "Nemocn\u00ED trp\u00EDc\u00ED schizofreni\u00ED maj\u00ED vy\u0161\u0161\u00ED riziko rozvoje kardi\u00E1ln\u00EDch onemocn\u011Bn\u00ED, je proto nutn\u00E9 vy\u0161et\u0159ovat u t\u011Bchto pacient\u016F stav kardiovaskul\u00E1rn\u00EDho syst\u00E9mu a monitorovat jejich t\u011Blesn\u00E9 zdrav\u00ED. Nemocn\u00ED se schizofreni\u00ED jsou ohro\u017Eeni \u010Dast\u011Bj\u0161\u00ED p\u0159\u00EDtomnost\u00ED faktor\u016F rizikov\u00FDch pro rozvoj kardiovaskul\u00E1rn\u00EDch chorob. Pat\u0159\u00ED mezi n\u011B obezita, kou\u0159en\u00ED, hypertenze, dyslipidemie a diabetes mellitus 2. typu. Myokarditidy a kardiomyopatie jsou vz\u00E1cn\u011B popisovan\u00E9 komplikace l\u00E9\u010Dby antipsychotiky. P\u0159esto\u017Ee jsou ob\u011B tyto komplikace vz\u00E1cn\u00E9, je d\u016Fle\u017Eit\u00E9 na n\u011B myslet, vzhledem k jejich potenci\u00E1ln\u011B fat\u00E1ln\u00EDmu pr\u016Fb\u011Bhu. Tento p\u0159ehled zd\u016Fraz\u0148uje roli psychiatra p\u0159i monitorov\u00E1n\u00ED suspektn\u00EDch kardiovaskul\u00E1rn\u00EDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F antipsychotik." . "11150" . . "3"^^ . . "3"^^ . . . "Nemocn\u00ED trp\u00EDc\u00ED schizofreni\u00ED maj\u00ED vy\u0161\u0161\u00ED riziko rozvoje kardi\u00E1ln\u00EDch onemocn\u011Bn\u00ED, je proto nutn\u00E9 vy\u0161et\u0159ovat u t\u011Bchto pacient\u016F stav kardiovaskul\u00E1rn\u00EDho syst\u00E9mu a monitorovat jejich t\u011Blesn\u00E9 zdrav\u00ED. Nemocn\u00ED se schizofreni\u00ED jsou ohro\u017Eeni \u010Dast\u011Bj\u0161\u00ED p\u0159\u00EDtomnost\u00ED faktor\u016F rizikov\u00FDch pro rozvoj kardiovaskul\u00E1rn\u00EDch chorob. Pat\u0159\u00ED mezi n\u011B obezita, kou\u0159en\u00ED, hypertenze, dyslipidemie a diabetes mellitus 2. typu. Myokarditidy a kardiomyopatie jsou vz\u00E1cn\u011B popisovan\u00E9 komplikace l\u00E9\u010Dby antipsychotiky. P\u0159esto\u017Ee jsou ob\u011B tyto komplikace vz\u00E1cn\u00E9, je d\u016Fle\u017Eit\u00E9 na n\u011B myslet, vzhledem k jejich potenci\u00E1ln\u011B fat\u00E1ln\u00EDmu pr\u016Fb\u011Bhu. Tento p\u0159ehled zd\u016Fraz\u0148uje roli psychiatra p\u0159i monitorov\u00E1n\u00ED suspektn\u00EDch kardiovaskul\u00E1rn\u00EDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F antipsychotik."@cs . . "Patients with schizophrenia are at increased risk of developing cardiac disease (CD) and there is well advised to screen CD and monitor patient\u00B4s physical health. Patients with schizophrenia are vulnerable to developing risk factors for cardiovascular disease, such as obesity, smoking, hypertension, dyslipidemia, and type 2 diabetes mellitus. Myocarditis and cardiomyopathy are rarely reported complications of antipsychotic treatment. Despite of rare occurrence, the awareness of these adverse events is important because of their potentially fatal outcome. This review underlines the psychiatrist's role in monitoring of suspected cardiac adverse effects of antipsychotics."@en . "465565" . "251;253" .